Discovery of a novel PLK1 inhibitor with high inhibitory potency using a combined virtual screening strategy
PLK1 is essential for cell cycle regulation and proliferation, and its elevated expression in prostate cancer is associated with high tumour grade. Therefore, PLK1 inhibition is considered a promising strategy for the treatment of prostate cancer. Here, we identified five compounds (Hits 1-5) target...
Saved in:
| Main Authors: | Zhen Xu, Lixia Guan, Yuting Wang, Miao-Miao Niu, Yashi Ruan, Cen Xu, Li Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2025.2467798 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Discovery of novel dual-targeting inhibitors against PLK1-PBD and PLK4-PB3: structure-guided pharmacophore modelling, virtual screening, molecular docking, molecular dynamics simulation, and biological evaluation
by: Changhao Zhao, et al.
Published: (2025-12-01) -
High-throughput virtual screening, identification and in vitro biological evaluation of novel inhibitors of PLK1 and NRP1
by: Yang Xia, et al.
Published: (2025-12-01) -
The status of p53 affects the efficacy of PLK1 inhibitor BI6727 in prostate cancer cells
by: Wenjing Li, et al.
Published: (2025-07-01) -
A potential tumor suppressor role of PLK2 in glioblastoma
by: Xiangping Xia, et al.
Published: (2025-05-01) -
PLK1 inhibition impairs erythroid differentiation
by: Peijun Jia, et al.
Published: (2024-12-01)